目次

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 26)
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
1.7.1 RECESSION IMPACT

2 RESEARCH METHODOLOGY (Page No. - 32)
2.1 RESEARCH APPROACH
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
FIGURE 2 CUSTOM ANTIBODY MARKET: PRIMARY RESPONDENTS
2.2 MARKET ESTIMATION METHODOLOGY
2.2.1 AVERAGE MARKET SIZE ESTIMATION (2022)
FIGURE 3 AVERAGE MARKET SIZE ESTIMATION (2022): GLOBAL MARKET
FIGURE 4 MARKET SIZE ESTIMATION: REVENUE-BASED ESTIMATION METHODOLOGY
2.3 DATA TRIANGULATION APPROACH
FIGURE 5 DATA TRIANGULATION METHODOLOGY
2.4 GROWTH RATE ASSUMPTIONS
2.5 GROWTH FORECAST
FIGURE 6 GROWTH RATE ANALYSIS
2.6 RISK ASSESSMENT
2.7 INSIGHTS FROM PRIMARY EXPERTS
2.8 GLOBAL MARKET: RECESSION IMPACT
TABLE 1 GLOBAL INFLATION RATE PROJECTION, 2021-2027 (% GROWTH)
TABLE 2 US HEALTH EXPENDITURE, 2019-2022 (USD MILLION)
TABLE 3 US HEALTH EXPENDITURE, 2023-2027 (USD MILLION)

3 EXECUTIVE SUMMARY (Page No. - 42)
FIGURE 7 GLOBAL MARKET, BY SERVICE, 2023 VS. 2028
FIGURE 8 GLOBAL MARKET SHARE, BY TYPE, 2023 VS. 2028
FIGURE 9 GLOBAL MARKET SHARE, BY SOURCE, 2023 VS. 2028
FIGURE 10 GLOBAL MARKET SHARE, BY APPLICATION, 2023 VS. 2028
FIGURE 11 GLOBAL MARKET SHARE, BY INDICATION, 2023 VS. 2028
FIGURE 12 GLOBAL MARKET SHARE, BY END USER, 2023 VS. 2028
FIGURE 13 GLOBAL MARKET: GEOGRAPHICAL SNAPSHOT

4 PREMIUM INSIGHTS (Page No. - 48)
4.1 CUSTOM ANTIBODY MARKET OVERVIEW
FIGURE 14 RISING DEMAND FOR MONOCLONAL ANTIBODIES IN THERAPEUTIC APPLICATIONS TO DRIVE MARKET
4.2 NORTH AMERICA: MARKET SHARE, BY TYPE & COUNTRY (2022)
FIGURE 15 MONOCLONAL ANTIBODIES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
4.3 GLOBAL MARKET SHARE, BY SOURCE (2022)
FIGURE 16 MICE SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
4.4 GLOBAL MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 17 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 51)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 18 GLOBAL MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
TABLE 4 GLOBAL MARKET: IMPACT ANALYSIS
5.2.1 DRIVERS
5.2.1.1 Rising research activities and funding investments for antibody development
5.2.1.2 Growing use of custom antibodies in precision medicine
5.2.1.3 Use of antibodies in biomarker identification and validation
5.2.1.4 Quality concerns over catalog antibodies
5.2.2 RESTRAINTS
5.2.2.1 High costs and complexities associated with antibody development
5.2.3 OPPORTUNITIES
5.2.3.1 Emerging markets
5.2.3.2 Rising therapeutic applications for mAbs
FIGURE 19 NUMBER OF APPROVED ANTIBODY THERAPEUTICS (2016−2022)
5.2.4 CHALLENGES
5.2.4.1 Challenges associated with immunization of host animals
5.2.4.2 Presence of alternative antibodies
5.3 VALUE CHAIN ANALYSIS
FIGURE 20 GLOBAL MARKET: VALUE-CHAIN ANALYSIS
5.4 ECOSYSTEM ANALYSIS
FIGURE 21 GLOBAL MARKET: ECOSYSTEM ANALYSIS
5.4.1 ROLE IN ECOSYSTEM
5.5 PORTER’S FIVE FORCES ANALYSIS
TABLE 5 GLOBAL MARKET: PORTER’S FIVE FORCES ANALYSIS
5.5.1 THREAT OF NEW ENTRANTS
5.5.2 THREAT OF SUBSTITUTES
5.5.3 BARGAINING POWER OF SUPPLIERS
5.5.4 BARGAINING POWER OF BUYERS
5.5.5 DEGREE OF COMPETITION
5.6 PATENT ANALYSIS
FIGURE 22 GLOBAL MARKET: PATENT ANALYSIS
5.7 PRICING ANALYSIS
5.7.1 AVERAGE SELLING PRICE TREND
5.7.2 INDICATIVE PRICING ANALYSIS
TABLE 6 SELLING PRICE OF SERVICES PROVIDED BY GENSCRIPT
TABLE 7 SELLING PRICE OF SERVICES PROVIDED BY ABBIOTEC, INC.
5.7.3 INDICATIVE PRICING ANALYSIS, BY REGION
TABLE 8 SELLING PRICE OF CUSTOM ANTIBODY SERVICES FOR INDIA
TABLE 9 SELLING PRICE OF CUSTOM ANTIBODY SERVICES FOR US
5.8 TECHNOLOGICAL ANALYSIS
5.8.1 CUSTOM ANTIBODY SERVICES
5.9 REGULATORY LANDSCAPE
5.9.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 10 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.10 KEY CONFERENCES & EVENTS IN 2023
TABLE 11 GLOBAL MARKET: DETAILED LIST OF CONFERENCES & EVENTS
5.11 KEY STAKEHOLDERS AND BUYING CRITERIA
FIGURE 23 KEY STAKEHOLDERS IN PHARMACEUTICAL COMPANIES AND THEIR INFLUENCE ON BUYING PROCESS
FIGURE 24 GLOBAL MARKET: KEY BUYING CRITERIA FOR END USERS
5.12 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 25 REVENUE SHIFT AND NEW REVENUE

6 CUSTOM ANTIBODY MARKET, BY SERVICE (Page No. - 69)
6.1 INTRODUCTION
TABLE 12 GLOBAL MARKET, BY SERVICE, 2021-2028 (USD MILLION)
6.2 ANTIBODY DEVELOPMENT
TABLE 13 GLOBAL MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021-2028 (USD MILLION)
TABLE 14 GLOBAL MARKET FOR ANTIBODY DEVELOPMENT, BY REGION, 2021-2028 (USD MILLION)
TABLE 15 NORTH AMERICA: MARKET FOR ANTIBODY DEVELOPMENT, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 16 EUROPE: MARKET FOR ANTIBODY DEVELOPMENT, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 17 ASIA PACIFIC: MARKET FOR ANTIBODY DEVELOPMENT MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 18 LATIN AMERICA: MARKET FOR ANTIBODY DEVELOPMENT, BY COUNTRY, 2021-2028 (USD MILLION)
6.2.1 ANTIBODY CHARACTERIZATION
6.2.1.1 Crucial step in research & biopharmaceutical development for elimination of antibodies to drive market
TABLE 19 GLOBAL MARKET FOR ANTIBODY CHARACTERIZATION, BY REGION, 2021-2028 (USD MILLION)
TABLE 20 NORTH AMERICA: MARKET FOR ANTIBODY CHARACTERIZATION, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 21 EUROPE: MARKET FOR ANTIBODY CHARACTERIZATION, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 22 ASIA PACIFIC: MARKET FOR ANTIBODY CHARACTERIZATION, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 23 LATIN AMERICA: MARKET FOR ANTIBODY CHARACTERIZATION, BY COUNTRY, 2021-2028 (USD MILLION)
6.2.2 ANTIGEN PREPARATION
6.2.2.1 Development of research antibodies using bioinformatics tools to support market growth
TABLE 24 GLOBAL MARKET FOR ANTIGEN PREPARATION, BY REGION, 2021-2028 (USD MILLION)
TABLE 25 NORTH AMERICA: MARKET FOR ANTIGEN PREPARATION, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 26 EUROPE: MARKET FOR ANTIGEN PREPARATION, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 27 ASIA PACIFIC: MARKET FOR ANTIGEN PREPARATION, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 28 LATIN AMERICA: MARKET FOR ANTIGEN PREPARATION, BY COUNTRY, 2021-2028 (USD MILLION)
6.2.3 IMMUNIZATION & HYBRIDOMA PRODUCTION
6.2.3.1 Rising demand for therapeutic antibodies to drive market
TABLE 29 GLOBAL MARKET FOR IMMUNIZATION & HYBRIDOMA PRODUCTION, BY REGION, 2021-2028 (USD MILLION)
TABLE 30 NORTH AMERICA: MARKET FOR IMMUNIZATION & HYBRIDOMA PRODUCTION, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 31 EUROPE: MARKET FOR IMMUNIZATION & HYBRIDOMA PRODUCTION, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 32 ASIA PACIFIC: MARKET FOR IMMUNIZATION & HYBRIDOMA PRODUCTION, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 33 LATIN AMERICA: MARKET FOR IMMUNIZATION & HYBRIDOMA PRODUCTION, BY COUNTRY, 2021-2028 (USD MILLION)
6.3 ANTIBODY PRODUCTION & PURIFICATION
6.3.1 RISING NEED FOR HIGH-QUALITY THERAPEUTICS TO DRIVE MARKET
TABLE 34 GLOBAL MARKET FOR ANTIBODY PRODUCTION & PURIFICATION, BY REGION, 2021-2028 (USD MILLION)
TABLE 35 NORTH AMERICA: MARKET FOR ANTIBODY PRODUCTION & PURIFICATION, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 36 EUROPE: MARKET FOR ANTIBODY PRODUCTION & PURIFICATION, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 37 ASIA PACIFIC: MARKET FOR ANTIBODY PRODUCTION & PURIFICATION, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 38 LATIN AMERICA: MARKET FOR ANTIBODY PRODUCTION & PURIFICATION, BY COUNTRY, 2021-2028 (USD MILLION)
6.4 ANTIBODY FRAGMENTATION & LABELING
6.4.1 RISING NEED FOR SPECIFIC ANTIBODIES IN DETECTION OF NEW BIOMOLECULES TO SUPPORT MARKET GROWTH
TABLE 39 GLOBAL MARKET FOR ANTIBODY FRAGMENTATION & LABELING. BY REGION, 2021-2028 (USD MILLION)
TABLE 40 NORTH AMERICA: MARKET FOR ANTIBODY FRAGMENTATION & LABELING, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 41 EUROPE: MARKET FOR ANTIBODY FRAGMENTATION & LABELING, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 42 ASIA PACIFIC: MARKET FOR ANTIBODY FRAGMENTATION & LABELING, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 43 LATIN AMERICA: MARKET FOR ANTIBODY FRAGMENTATION & LABELING, BY COUNTRY, 2021-2028 (USD MILLION)

7 CUSTOM ANTIBODY MARKET, BY TYPE (Page No. - 89)
7.1 INTRODUCTION
TABLE 44 GLOBAL MARKET, BY TYPE, 2021-2028 (USD MILLION)
7.2 MONOCLONAL ANTIBODIES
7.2.1 HIGH DEGREE OF SENSITIVITY AND PRECISION TO DRIVE MARKET
TABLE 45 GLOBAL MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2021-2028 (USD MILLION)
TABLE 46 NORTH AMERICA: MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 47 EUROPE: MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 48 ASIA PACIFIC: MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 49 LATIN AMERICA: MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION)
7.3 POLYCLONAL ANTIBODIES
7.3.1 ABILITY TO BE STABLE AND WITHSTAND VARIATIONS IN TEMPERATURE TO FUEL UPTAKE
TABLE 50 GLOBAL MARKET FOR POLYCLONAL ANTIBODIES, BY TYPE, BY REGION, 2021-2028 (USD MILLION)
TABLE 51 NORTH AMERICA: MARKET FOR POLYCLONAL ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 52 EUROPE: MARKET FOR POLYCLONAL ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 53 ASIA PACIFIC: MARKET FOR POLYCLONAL ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 54 LATIN AMERICA: MARKET FOR POLYCLONAL ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION)
7.4 RECOMBINANT ANTIBODIES
7.4.1 LOW IMMUNOGENICITY AND RISING RESEARCH REPRODUCIBILITY TO DRIVE MARKET
TABLE 55 GLOBAL MARKET FOR RECOMBINANT ANTIBODIES, BY REGION, 2021-2028 (USD MILLION)
TABLE 56 NORTH AMERICA: MARKET FOR RECOMBINANT ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 57 EUROPE: MARKET FOR RECOMBINANT ANTIBODIES, 2021-2028 (USD MILLION)
TABLE 58 ASIA PACIFIC: MARKET FOR RECOMBINANT ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 59 LATIN AMERICA: MARKET FOR RECOMBINANT ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION)
7.5 OTHER CUSTOM ANTIBODIES
TABLE 60 OTHER CUSTOM ANTIBODIES MARKET, BY REGION, 2021-2028 (USD MILLION)
TABLE 61 NORTH AMERICA: OTHER CUSTOM ANTIBODIES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 62 EUROPE: OTHER CUSTOM ANTIBODIES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 63 ASIA PACIFIC: OTHER CUSTOM ANTIBODIES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 64 LATIN AMERICA: OTHER CUSTOM ANTIBODIES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)

8 CUSTOM ANTIBODY MARKET, BY SOURCE (Page No. - 102)
8.1 INTRODUCTION
TABLE 65 GLOBAL MARKET, BY SOURCE, 2021-2028 (USD MILLION)
8.2 MICE
8.2.1 CONVENTIONALLY PREFERRED HOSTS FOR MAB PRODUCTION TO INCREASE UPTAKE
TABLE 66 GLOBAL MARKET FOR MICE, BY REGION, 2021-2028 (USD MILLION)
TABLE 67 NORTH AMERICA: MARKET FOR MICE, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 68 EUROPE: MARKET FOR MICE, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 69 ASIA PACIFIC: MARKET FOR MICE, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 70 LATIN AMERICA: MARKET FOR MICE, BY COUNTRY, 2021-2028 (USD MILLION)
8.3 RABBITS
8.3.1 ABILITY TO GENERATE HIGH ANTIBODY DIVERSITY WITH OPTIMAL AFFINITY TO DRIVE MARKET
TABLE 71 GLOBAL MARKET FOR RABBITS, BY REGION, 2021-2028 (USD MILLION)
TABLE 72 NORTH AMERICA: MARKET FOR RABBITS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 73 EUROPE: MARKET FOR RABBITS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 74 ASIA PACIFIC: MARKET FOR RABBITS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 75 LATIN AMERICA: MARKET FOR RABBITS, BY COUNTRY, 2021-2028 (USD MILLION)
8.4 OTHER SOURCES
TABLE 76 GLOBAL MARKET FOR OTHER SOURCES, BY REGION, 2021-2028 (USD MILLION)
TABLE 77 NORTH AMERICA: MARKET FOR OTHER SOURCES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 78 EUROPE: MARKET FOR OTHER SOURCES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 79 ASIA PACIFIC: MARKET FOR OTHER SOURCES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 80 LATIN AMERICA: MARKET FOR OTHER SOURCES, BY COUNTRY, 2021-2028 (USD MILLION)

9 CUSTOM ANTIBODY MARKET, BY APPLICATION (Page No. - 111)
9.1 INTRODUCTION
TABLE 81 GLOBAL MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
9.2 RESEARCH
9.2.1 RISING R&D ACTIVITIES FOR MAB-BASED THERAPEUTICS TO DRIVE MARKET
TABLE 82 GLOBAL MARKET FOR RESEARCH, BY REGION, 2021-2028 (USD MILLION)
TABLE 83 NORTH AMERICA: MARKET FOR RESEARCH, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 84 EUROPE: MARKET FOR RESEARCH, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 85 ASIA PACIFIC: MARKET FOR RESEARCH, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 86 LATIN AMERICA: MARKET FOR RESEARCH, BY COUNTRY, 2021-2028 (USD MILLION)
9.3 THERAPEUTICS
9.3.1 GROWING USE OF MABS IN TARGETED THERAPY FOR AUTOIMMUNE DISEASES TO DRIVE MARKET
TABLE 87 GLOBAL MARKET FOR THERAPEUTICS, BY REGION, 2021-2028 (USD MILLION)
TABLE 88 NORTH AMERICA: MARKET FOR THERAPEUTICS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 89 EUROPE: MARKET FOR THERAPEUTICS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 90 ASIA PACIFIC: MARKET FOR THERAPEUTICS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 91 LATIN AMERICA: MARKET FOR THERAPEUTICS, BY COUNTRY, 2021-2028 (USD MILLION)

10 CUSTOM ANTIBODY MARKET, BY INDICATION (Page No. - 119)
10.1 INTRODUCTION
TABLE 92 GLOBAL MARKET, BY INDICATION, 2021-2028 (USD MILLION)
10.2 ONCOLOGY
10.2.1 GROWING USE OF MABS IN CANCER TREATMENT TO DRIVE MARKET
TABLE 93 GLOBAL MARKET FOR ONCOLOGY, BY REGION, 2021-2028 (USD MILLION)
TABLE 94 NORTH AMERICA: MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 95 EUROPE: MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 96 ASIA PACIFIC: MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 97 LATIN AMERICA: MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
10.3 INFECTIOUS DISEASES
10.3.1 WIDE USAGE OF ANTIBODIES IN VACCINE & THERAPEUTIC DEVELOPMENT TO DRIVE MARKET
TABLE 98 GLOBAL MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021-2028 (USD MILLION)
TABLE 99 NORTH AMERICA: MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 100 EUROPE: MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 101 ASIA PACIFIC: MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 102 LATIN AMERICA: MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
10.4 IMMUNOLOGY
10.4.1 RISING DEMAND FOR THERAPEUTIC ANTIBODIES IN IMMUNOLOGY TO DRIVE MARKET
TABLE 103 GLOBAL MARKET FOR IMMUNOLOGY, BY REGION, 2021-2028 (USD MILLION)
TABLE 104 NORTH AMERICA: MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 105 EUROPE: MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 106 ASIA PACIFIC: MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 107 LATIN AMERICA: MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
10.5 NEUROBIOLOGY
10.5.1 RISING DEMAND FOR ANTIBODIES IN NEURODEGENERATIVE DISEASE TREATMENT TO DRIVE MARKET
TABLE 108 GLOBAL MARKET FOR NEUROBIOLOGY, BY REGION, 2021-2028 (USD MILLION)
TABLE 109 NORTH AMERICA: MARKET FOR NEUROBIOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 110 EUROPE: MARKET FOR NEUROBIOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 111 ASIA PACIFIC: MARKET FOR NEUROBIOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 112 LATIN AMERICA: MARKET FOR NEUROBIOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
10.6 CARDIOVASCULAR DISEASES
10.6.1 GROWING DEMAND FOR CVD BIOMARKERS TO DRIVE MARKET
TABLE 113 GLOBAL MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2021-2028 (USD MILLION)
TABLE 114 NORTH AMERICA: MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 115 EUROPE: MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 116 ASIA PACIFIC: MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 117 LATIN AMERICA: MARKET FOR CARDIOVASCULAR DISEASE, BY COUNTRY, 2021-2028 (USD MILLION)
10.7 OTHER INDICATIONS
TABLE 118 GLOBAL MARKET FOR OTHER INDICATIONS, BY REGION, 2021-2028 (USD MILLION)
TABLE 119 NORTH AMERICA: MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 120 EUROPE: MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 121 ASIA PACIFIC: MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 122 LATIN AMERICA: MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)

11 CUSTOM ANTIBODY MARKET, BY END USER (Page No. - 136)
11.1 INTRODUCTION
TABLE 123 GLOBAL MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 124 GLOBAL MARKET, BY REGION, 2021-2028 (USD MILLION)
TABLE 125 NORTH AMERICA: MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 126 EUROPE: MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 127 ASIA PACIFIC: MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 128 LATIN AMERICA: MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
11.2.1 RISING NEED FOR ANTIBODIES IN BIOMARKER QUANTIFICATION TO DRIVE MARKET
TABLE 129 GLOBAL MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021-2028 (USD MILLION)
TABLE 130 NORTH AMERICA: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 131 EUROPE: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 132 ASIA PACIFIC: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 133 LATIN AMERICA: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)
11.3 ACADEMIC & RESEARCH INSTITUTES
11.3.1 GROWING INDUSTRY-ACADEMIA COLLABORATIONS AND RISING GOVERNMENT-FUNDED INITIATIVES TO DRIVE MARKET
TABLE 134 GLOBAL MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2021-2028 (USD MILLION)
TABLE 135 NORTH AMERICA: MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 136 EUROPE: MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 137 ASIA PACIFIC: MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 138 LATIN AMERICA: MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION)
11.4 CONTRACT RESEARCH ORGANIZATIONS
11.4.1 ABILITY TO PROVIDE SPECIALIZED SERVICES FOR PRODUCTION OF MABS & ADCS TO SUPPORT MARKET GROWTH
TABLE 139 GLOBAL MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2021-2028 (USD MILLION)
TABLE 140 NORTH AMERICA: MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 141 EUROPE: MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 142 ASIA PACIFIC: MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 143 LATIN AMERICA: MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021-2028 (USD MILLION)

12 CUSTOM ANTIBODY MARKET, BY REGION (Page No. - 149)
12.1 INTRODUCTION
TABLE 144 GLOBAL MARKET, BY REGION, 2021-2028 (USD MILLION)
12.2 NORTH AMERICA
FIGURE 26 NORTH AMERICA: CUSTOM ANTIBODY MARKET SNAPSHOT
TABLE 145 NORTH AMERICA: MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 146 NORTH AMERICA: MARKET, BY SERVICE, 2021-2028 (USD MILLION)
TABLE 147 NORTH AMERICA: MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021-2028 (USD MILLION)
TABLE 148 NORTH AMERICA: MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 149 NORTH AMERICA: MARKET, BY SOURCE, 2021-2028 (USD MILLION)
TABLE 150 NORTH AMERICA: MARKET, BY INDICATION, 2021-2028 (USD MILLION)
TABLE 151 NORTH AMERICA: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 152 NORTH AMERICA: MARKET, BY END USER, 2021-2028 (USD MILLION)
12.2.1 US
12.2.1.1 Rising research in structure-based drug design and therapeutic mAbs to drive market
TABLE 153 US: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021-2028 (USD MILLION)
TABLE 154 US: MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021-2028 (USD MILLION)
TABLE 155 US: MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 156 US: MARKET, BY SOURCE, 2021-2028 (USD MILLION)
TABLE 157 US: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 158 US: MARKET, BY INDICATION, 2021-2028 (USD MILLION)
TABLE 159 US: MARKET, BY END USER, 2021-2028 (USD MILLION)
12.2.2 CANADA
12.2.2.1 Increasing genomic research to fuel market uptake
TABLE 160 CANADA: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021-2028 (USD MILLION)
TABLE 161 CANADA: MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021-2028 (USD MILLION)
TABLE 162 CANADA: MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 163 CANADA: MARKET, BY SOURCE, 2021-2028 (USD MILLION)
TABLE 164 CANADA: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 165 CANADA: MARKET, BY INDICATION, 2021-2028 (USD MILLION)
TABLE 166 CANADA: MARKET, BY END USER, 2021-2028 (USD MILLION)
12.2.3 NORTH AMERICA: RECESSION IMPACT
12.3 EUROPE
TABLE 167 EUROPE: CUSTOM ANTIBODY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 168 EUROPE: MARKET, BY SERVICE, 2021-2028 (USD MILLION)
TABLE 169 EUROPE: MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021-2028 (USD MILLION)
TABLE 170 EUROPE: MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 171 EUROPE: MARKET, BY SOURCE, 2021-2028 (USD MILLION)
TABLE 172 EUROPE: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 173 EUROPE: MARKET, BY INDICATION, 2021-2028 (USD MILLION)
TABLE 174 EUROPE: MARKET, BY END USER, 2021-2028 (USD MILLION)
12.3.1 GERMANY
12.3.1.1 High investments in development of ADCs to drive market
TABLE 175 GERMANY: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021-2028 (USD MILLION)
TABLE 176 GERMANY: MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021-2028 (USD MILLION)
TABLE 177 GERMANY: MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 178 GERMANY: MARKET, BY SOURCE, 2021-2028 (USD MILLION)
TABLE 179 GERMANY: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 180 GERMANY: MARKET, BY INDICATION, 2021-2028 (USD MILLION)
TABLE 181 GERMANY: MARKET, BY END USER, 2021-2028 (USD MILLION)
12.3.2 UK
12.3.2.1 Rising pharmaceutical spending and growing life sciences industry to drive market
TABLE 182 UK: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021-2028 (USD MILLION)
TABLE 183 UK: MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021-2028 (USD MILLION)
TABLE 184 UK: MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 185 UK: MARKET, BY SOURCE, 2021-2028 (USD MILLION)
TABLE 186 UK: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 187 UK: MARKET, BY INDICATION, 2021-2028 (USD MILLION)
TABLE 188 UK: MARKET, BY END USER, 2021-2028 (USD MILLION)
12.3.3 FRANCE
12.3.3.1 Growing pipeline of therapeutic mAbs coupled with rising research investments to support market growth
TABLE 189 FRANCE: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021-2028 (USD MILLION)
TABLE 190 FRANCE: MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021-2028 (USD MILLION)
TABLE 191 FRANCE: MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 192 FRANCE: MARKET, BY SOURCE, 2021-2028 (USD MILLION)
TABLE 193 FRANCE: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 194 FRANCE: MARKET, BY INDICATION, 2021-2028 (USD MILLION)
TABLE 195 FRANCE: MARKET, BY END USER, 2021-2028 (USD MILLION)
12.3.4 ITALY
12.3.4.1 Increasing research activities in proteomics & genomics to drive market
TABLE 196 ITALY: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021-2028 (USD MILLION)
TABLE 197 ITALY: MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021-2028 (USD MILLION)
TABLE 198 ITALY: MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 199 ITALY: MARKET, BY SOURCE, 2021-2028 (USD MILLION)
TABLE 200 ITALY: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 201 ITALY: MARKET, BY INDICATION, 2021-2028 (USD MILLION)
TABLE 202 ITALY: MARKET, BY END USER, 2021-2028 (USD MILLION)
12.3.5 SPAIN
12.3.5.1 Growing focus on advancements in personalized medicine to support market growth
TABLE 203 SPAIN: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021-2028 (USD MILLION)
TABLE 204 SPAIN: MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021-2028 (USD MILLION)
TABLE 205 SPAIN: MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 206 SPAIN: MARKET, BY SOURCE, 2021-2028 (USD MILLION)
TABLE 207 SPAIN: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 208 SPAIN: MARKET, BY INDICATION, 2021-2028 (USD MILLION)
TABLE 209 SPAIN: MARKET, BY END USER, 2021-2028 (USD MILLION)
12.3.6 REST OF EUROPE
TABLE 210 REST OF EUROPE: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021-2028 (USD MILLION)
TABLE 211 REST OF EUROPE: MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021-2028 (USD MILLION)
TABLE 212 REST OF EUROPE: MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 213 REST OF EUROPE: MARKET, BY SOURCE, 2021-2028 (USD MILLION)
TABLE 214 REST OF EUROPE: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 215 REST OF EUROPE: MARKET, BY INDICATION, 2021-2028 (USD MILLION)
TABLE 216 REST OF EUROPE: MARKET, BY END USER, 2021-2028 (USD MILLION)
12.3.7 EUROPE: RECESSION IMPACT
12.4 ASIA PACIFIC
FIGURE 27 ASIA PACIFIC: CUSTOM ANTIBODY MARKET SNAPSHOT
TABLE 217 ASIA PACIFIC: MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 218 ASIA PACIFIC: MARKET, BY SERVICE, 2021-2028 (USD MILLION)
TABLE 219 ASIA PACIFIC: MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021-2028 (USD MILLION)
TABLE 220 ASIA PACIFIC: MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 221 ASIA PACIFIC: MARKET, BY SOURCE, 2021-2028 (USD MILLION)
TABLE 222 ASIA PACIFIC: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 223 ASIA PACIFIC: MARKET, BY INDICATION, 2021-2028 (USD MILLION)
TABLE 224 ASIA PACIFIC: MARKET, BY END USER, 2021-2028 (USD MILLION)
12.4.1 JAPAN
12.4.1.1 Rising research activities for development of ADCs to drive market
TABLE 225 JAPAN: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021-2028 (USD MILLION)
TABLE 226 JAPAN: MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021-2028 (USD MILLION)
TABLE 227 JAPAN: MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 228 JAPAN: MARKET, BY SOURCE, 2021-2028 (USD MILLION)
TABLE 229 JAPAN: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 230 JAPAN: MARKET, BY INDICATION, 2021-2028 (USD MILLION)
TABLE 231 JAPAN: MARKET, BY END USER, 2021-2028 (USD MILLION)
12.4.2 CHINA
12.4.2.1 Increasing establishment of R&D facilities to fuel uptake
TABLE 232 CHINA: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021-2028 (USD MILLION)
TABLE 233 CHINA: MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021-2028 (USD MILLION)
TABLE 234 CHINA: MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 235 CHINA: MARKET, BY SOURCE, 2021-2028 (USD MILLION)
TABLE 236 CHINA: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 237 CHINA: MARKET, BY INDICATION, 2021-2028 (USD MILLION)
TABLE 238 CHINA: MARKET, BY END USER, 2021-2028 (USD MILLION)
12.4.3 SOUTH KOREA
12.4.3.1 Increasing research on therapeutic antibodies and cytokines to support market growth
TABLE 239 SOUTH KOREA: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021-2028 (USD MILLION)
TABLE 240 SOUTH KOREA: MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021-2028 (USD MILLION)
TABLE 241 SOUTH KOREA: MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 242 SOUTH KOREA: MARKET, BY SOURCE, 2021-2028 (USD MILLION)
TABLE 243 SOUTH KOREA: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 244 SOUTH KOREA: MARKET, BY INDICATION, 2021-2028 (USD MILLION)
TABLE 245 SOUTH KOREA: MARKET, BY END USER, 2021-2028 (USD MILLION)
12.4.4 INDIA
12.4.4.1 High pharmaceutical R&D spending to support market growth
TABLE 246 INDIA: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021-2028 (USD MILLION)
TABLE 247 INDIA: MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021-2028 (USD MILLION)
TABLE 248 INDIA: MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 249 INDIA: MARKET, BY SOURCE, 2021-2028 (USD MILLION)
TABLE 250 INDIA: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 251 INDIA: MARKET, BY INDICATION, 2021-2028 (USD MILLION)
TABLE 252 INDIA: MARKET, BY END USER, 2021-2028 (USD MILLION)
12.4.5 REST OF ASIA PACIFIC
TABLE 253 REST OF ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021-2028 (USD MILLION)
TABLE 254 REST OF ASIA PACIFIC: MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021-2028 (USD MILLION)
TABLE 255 REST OF ASIA PACIFIC: MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 256 REST OF ASIA PACIFIC: MARKET, BY SOURCE, 2021-2028 (USD MILLION)
TABLE 257 REST OF ASIA PACIFIC: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 258 REST OF ASIA PACIFIC: MARKET, BY INDICATION, 2021-2028 (USD MILLION)
TABLE 259 REST OF ASIA PACIFIC: MARKET, BY END USER, 2021-2028 (USD MILLION)
12.4.6 ASIA PACIFIC: RECESSION IMPACT
12.5 LATIN AMERICA
TABLE 260 LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 261 LATIN AMERICA: MARKET, BY SERVICE, 2021-2028 (USD MILLION)
TABLE 262 LATIN AMERICA: MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021-2028 (USD MILLION)
TABLE 263 LATIN AMERICA: MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 264 LATIN AMERICA: MARKET, BY SOURCE, 2021-2028 (USD MILLION)
TABLE 265 LATIN AMERICA: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 266 LATIN AMERICA: MARKET, BY INDICATION, 2021-2028 (USD MILLION)
TABLE 267 LATIN AMERICA: MARKET, BY END USER, 2021-2028 (USD MILLION)
12.5.1 BRAZIL
12.5.1.1 Utilization of therapeutic antibodies for oncology applications to support market growth
TABLE 268 BRAZIL: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021-2028 (USD MILLION)
TABLE 269 BRAZIL: MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021-2028 (USD MILLION)
TABLE 270 BRAZIL: MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 271 BRAZIL: MARKET, BY SOURCE, 2021-2028 (USD MILLION)
TABLE 272 BRAZIL: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 273 BRAZIL: MARKET, BY INDICATION, 2021-2028 (USD MILLION)
TABLE 274 BRAZIL: MARKET, BY END USER, 2021-2028 (USD MILLION)
12.5.2 REST OF LATIN AMERICA
TABLE 275 REST OF LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021-2028 (USD MILLION)
TABLE 276 REST OF LATIN AMERICA: MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021-2028 (USD MILLION)
TABLE 277 REST OF LATIN AMERICA: MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 278 REST OF LATIN AMERICA: MARKET, BY SOURCE, 2021-2028 (USD MILLION)
TABLE 279 REST OF LATIN AMERICA: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 280 REST OF LATIN AMERICA: MARKET, BY INDICATION, 2021-2028 (USD MILLION)
TABLE 281 REST OF LATIN AMERICA: MARKET, BY END USER, 2021-2028 (USD MILLION)
12.5.3 LATIN AMERICA: RECESSION IMPACT
12.6 MIDDLE EAST & AFRICA
12.6.1 INCREASING RESEARCH COLLABORATIONS AND DEVELOPING HEALTHCARE INFRASTRUCTURE TO SUPPORT MARKET GROWTH
TABLE 282 MIDDLE EAST & AFRICA: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021-2028 (USD MILLION)
TABLE 283 MIDDLE EAST & AFRICA: MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021-2028 (USD MILLION)
TABLE 284 MIDDLE EAST & AFRICA: MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 285 MIDDLE EAST & AFRICA: MARKET, BY SOURCE, 2021-2028 (USD MILLION)
TABLE 286 MIDDLE EAST & AFRICA: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 287 MIDDLE EAST & AFRICA: MARKET, BY INDICATION, 2021-2028 (USD MILLION)
TABLE 288 MIDDLE EAST & AFRICA: MARKET, BY END USER, 2021-2028 (USD MILLION)
12.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT

13 COMPETITIVE LANDSCAPE (Page No. - 216)
13.1 INTRODUCTION
13.2 STRATEGIES ADOPTED BY KEY MARKET PLAYERS
13.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
FIGURE 28 CUSTOM ANTIBODY MARKET: REVENUE SHARE ANALYSIS OF LEADING PLAYERS
13.4 MARKET SHARE ANALYSIS
FIGURE 29 GLOBAL MARKET: MARKET SHARE ANALYSIS OF LEADING PLAYERS (2022)
TABLE 289 GLOBAL MARKET: INTENSITY OF COMPETITIVE RIVALRY
13.5 COMPANY EVALUATION QUADRANT
13.5.1 STARS
13.5.2 EMERGING LEADERS
13.5.3 PERVASIVE PLAYERS
13.5.4 PARTICIPANTS
FIGURE 30 GLOBAL MARKET: COMPANY EVALUATION QUADRANT
13.6 COMPANY EVALUATION QUADRANT FOR STARTUPS (2022)
13.6.1 PROGRESSIVE COMPANIES
13.6.2 STARTING BLOCKS
13.6.3 RESPONSIVE COMPANIES
13.6.4 DYNAMIC COMPANIES
FIGURE 31 GLOBAL MARKET: COMPANY EVALUATION QUADRANT FOR STARTUPS (2022)
13.7 COMPANY FOOTPRINT
13.8 COMPANY SERVICE FOOTPRINT
TABLE 290 GLOBAL MARKET: SERVICE PORTFOLIO ANALYSIS (2022)
13.9 COMPANY GEOGRAPHIC FOOTPRINT
TABLE 291 GLOBAL MARKET: GEOGRAPHIC REVENUE MIX (2022)
13.1 KEY STRATEGIES ADOPTED BY MARKET PLAYERS
13.10.1 GLOBAL MARKET: KEY DEALS (JANUARY 2020 TO JANUARY 2023)
13.10.2 GLOBAL MARKET: KEY EXPANSIONS (JANUARY 2020 TO JANUARY 2023)

14 COMPANY PROFILES (Page No. - 228)
(Business overview, Services offered, Recent developments, Other developments & MnM View)*
14.1 KEY MARKET PLAYERS
14.1.1 THERMO FISHER SCIENTIFIC, INC.
TABLE 292 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
FIGURE 32 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2021)
TABLE 293 THERMO FISHER SCIENTIFIC, INC.: DEALS
14.1.2 GENSCRIPT
TABLE 294 GENSCRIPT: BUSINESS OVERVIEW
FIGURE 33 GENSCRIPT: COMPANY SNAPSHOT (2021)
TABLE 295 GENSCRIPT: DEALS
14.1.3 ABCAM PLC.
TABLE 296 ABCAM PLC.: BUSINESS OVERVIEW
FIGURE 34 ABCAM PLC.: COMPANY SNAPSHOT (2021)
TABLE 297 ABCAM PLC.: DEALS
14.1.4 CELL SIGNALING TECHNOLOGY, INC.
TABLE 298 CELL SIGNALING TECHNOLOGY, INC.: BUSINESS OVERVIEW
14.1.5 BIO-RAD LABORATORIES, INC.
TABLE 299 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
FIGURE 35 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2021)
14.1.6 MERCK KGAA
TABLE 300 MERCK KGAA.: BUSINESS OVERVIEW
FIGURE 36 MERCK KGAA: COMPANY SNAPSHOT (2021)
TABLE 301 MERCK KGAA: DEALS
14.1.7 AGILENT TECHNOLOGIES, INC.
TABLE 302 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW
FIGURE 37 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2021)
14.1.8 PERKINELMER, INC.
TABLE 303 PERKINELMER, INC.: BUSINESS OVERVIEW
FIGURE 38 PERKINELMER, INC.: COMPANY SNAPSHOT (2021)
14.1.9 ROCKLAND IMMUNOCHEMICALS, INC.
TABLE 304 ROCKLAND IMMUNOCHEMICALS, INC.: BUSINESS OVERVIEW
TABLE 305 ROCKLAND IMMUNOCHEMICALS, INC.: DEALS
14.1.10 PROMAB BIOTECHNOLOGIES, INC.
TABLE 306 PROMAB BIOTECHNOLOGIES, INC.: BUSINESS OVERVIEW
14.1.11 INNOVAGEN AB
TABLE 307 INNOVAGEN AB: BUSINESS OVERVIEW
14.1.12 ORIGENE TECHNOLOGIES INC.
TABLE 308 ORIGENE TECHNOLOGIES INC.: BUSINESS OVERVIEW
14.1.13 BIO-TECHNE
TABLE 309 BIO-TECHNE: BUSINESS OVERVIEW
FIGURE 39 BIO-TECHNE: COMPANY SNAPSHOT (2021)
TABLE 310 BIO-TECHNE: DEALS
14.1.14 CREATIVE DIAGNOSTICS
TABLE 311 CREATIVE DIAGNOSTICS: BUSINESS OVERVIEW
14.1.15 SINO BIOLOGICAL, INC.
TABLE 312 SINO BIOLOGICAL, INC.: BUSINESS OVERVIEW
FIGURE 40 SINO BIOLOGICAL, INC.: COMPANY SNAPSHOT (2021)
*Details on Business overview, Services offered, Recent developments, Other developments & MnM View might not be captured in case of unlisted companies.
14.2 OTHER PLAYERS
14.2.1 RAYBIOTECH LIFE, INC.
14.2.2 ABBIOTEC, INC.
14.2.3 PROSCI INCORPORATED
14.2.4 BOSTER BIOLOGICAL TECHNOLOGY
14.2.5 CUSABIO TECHNOLOGY LLC
14.2.6 BIOINTRON
14.2.7 KANEKA EUROGENTEC S.A.
14.2.8 CREATIVE BIOLABS
14.2.9 ENVIGO
14.2.10 IMGENEX INDIA

15 APPENDIX (Page No. - 270)
15.1 DISCUSSION GUIDE
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
15.3 CUSTOMIZATION OPTIONS
15.4 RELATED REPORTS
15.5 AUTHOR DETAILS